Serum samples were assayed at three dilutions (40%, 1%, and 0.005%) with each sample dilution added to a corresponding subset of the 1,305 SOMAmer detection reagents binned according to manufacturer’s predicted target abundance in serum. Cerebrospinal fluid was run at a single 15% concentration dilution with protease inhibitors and polyanionic competitor reagent added.
Label
n/a
Label protocol
Labeling was performed according to manufacturers instructions for the SOMAscan Assay v3.2 standard protocol (SomaLogic, Boulder, CO, USA).
Hybridization protocol
Hypbridization was performed according to manufacturers instructions for the SOMAscan Assay v3.2 standard protocol (SomaLogic, Boulder, CO, USA).
Scan protocol
Scanning was performed according to manufacturers instructions for the SOMAscan Assay v3.2 standard protocol (SomaLogic, Boulder, CO, USA).
Description
Patient
Data processing
Data processing was performed according to manufacturers instructions for the SOMAscan Assay v3.2 standard protocol (SomaLogic, Boulder, CO, USA). In brief, systematic effects on the data introduced during the hybridization step were corrected followed by median normalization (i.e., hybNorm.plateScale.medNorm).
